<DOC>
	<DOCNO>NCT01236560</DOCNO>
	<brief_summary>This randomized phase II/III trial study vorinostat , temozolomide , bevacizumab see well work compare give together radiation therapy follow bevacizumab temozolomide treat young patient newly diagnose high-grade glioma . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . It yet know whether give vorinostat effective temozolomide bevacizumab give together radiation therapy treat glioma .</brief_summary>
	<brief_title>Vorinostat , Temozolomide , Bevacizumab Combination With Radiation Therapy Followed Bevacizumab Temozolomide Young Patients With Newly Diagnosed High-Grade Glioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To identify dose vorinostat feasible give combination radiotherapy ( RT ) patient newly diagnose high-grade glioma ( HGG ) . II . To compare 1-year event-free survival patient newly diagnose HGG treat vorinostat ( use MTD ) versus bevacizumab versus temozolomide give combination RT follow maintenance therapy bevacizumab temozolomide . ( Phase II ) III . To compare event-free survival patient newly diagnose HGG treat superior chemoradiotherapy ( phase II portion ) versus temozolomide give combination RT follow maintenance chemotherapy bevacizumab temozolomide . ( Phase III ) SECONDARY OBJECTIVES : I . To evaluate anti-tumor activity , measure event-free survival ( EFS ) , progression-free survival ( PFS ) , overall survival ( OS ) , patient newly diagnose HGG treat vorinostat , bevacizumab , temozolomide give combination RT follow maintenance chemotherapy bevacizumab temozolomide . II . To define evaluate toxicity treatment arm study . III . To conduct gene expression profile SNP array patient newly diagnose HGG . IV . To assess telomerase activity , hTert expression , telomere length patient newly diagnose HGG . V. To document change perfusion diffusion use MR image baseline , prior , ( prior course 3 ) , maintenance therapy bevacizumab temozolomide . VI . To correlate functional change tumor response bevacizumab treatment use MR diffusion/perfusion image . VII . To correlate result bevacizumab biology study serum tumor EFS . VIII . To explore prognostic significance MGMT status patient newly diagnose HGG treat combined surgery , radiation , chemotherapy , anti-angiogenic therapy . OUTLINE : This multicenter , feasibility , dose-escalation study vorinostat , follow phase II study , follow phase III study . FEASIBILITY STUDY : Patients undergo 3-D conformal radiotherapy ( RT ) intensity-modulated RT 5 day week 6 week . Patients also receive vorinostat orally ( PO ) daily day 1-5 . Courses repeat every week 6 week absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Beginning 4 week completion chemoradiotherapy , patient receive bevacizumab IV 30-90 minute day 1 15 temozolomide PO day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . PHASE II STUDY : Patients stratify accord extent resection ( near total resection gross total resection v ) histology ( glioblastoma multiforme v ) . Patients randomize 1 3 treatment arm . ARM I : Patients undergo RT 5 day week 6 week receive vorinostat maximum-tolerated dose determine feasibility study . ARM II : Patients undergo RT arm I receive temozolomide PO daily 42 day begin day 5 RT . ARM III : Patients undergo RT arm I receive bevacizumab IV 30-90 minute day 22 36 . Patients arm receive maintenance therapy feasibility study . PHASE III study : Patients randomize 1 2 treatment arm . ARM IV : Patients receive RT temozolomide phase II , arm II . ARM V : Patients receive treatment phase II , arm I phase II , arm III , whichever establish superior chemoradiotherapy arm phase II . Patients arm receive maintenance therapy feasibility study . Some patient undergo blood tumor tissue sample ( surgery ) collection telomerase activity , hTert expression , telomere length , gene expression profile SNP array analysis . After completion study therapy , patient follow every 3 month 1 year , every 6 month 4 year , annually 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Newly diagnose highgrade glioma Anaplastic astrocytoma Glioblastomamultiforme Gliosarcoma Primary spinal cord malignant glioma allow No oligodendroglioma oroligoastrocytoma Patient must histological verification diagnosis No M+ disease ( defined evidence neuraxis dissemination ) No positive CSF cytology ECOG performance status ( PS ) 02 Karnofsky PS 50100 % ( patient &gt; 16 year age ) Lansky PS 50100 % ( patient ≤ 16 year age ) ANC ≥ 1,000/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 8.0 mg/dL ( transfusion independent ) Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age and/or gender follow : 0.4 mg/dL ( 1 month &lt; 6 month age ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( ≥ 16 year age ) Proteinuria &lt; 2+ OR urine ; protein ratio ( UPC ) ≤ 0.5 If UPC &gt; 0.5 , 24hour urine protein obtain level &lt; 1,000 mg protein Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 2.5 time ULN Serum albumin ≥ 2 g/dL PT INR ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study therapy ≥ 6 month completion bevacizumab Hypertension well control ( ≤ 95^th percentile age height patient ≤ 17years ) stable dos medication allow For patient &gt; 17 year , systolic blood pressure ( BP ) ≤ 150 mm Hg diastolic BP ≤ 100 mm Hg ) Seizure disorder allow provided patient wellcontrolled nonenzymeinducing anticonvulsant No history myocardial infarction , severe unstable angina , clinically significant peripheral vascular disease , ≥ grade 2 heart failure , serious inadequately control cardiac arrhythmia No known bleed diathesis coagulopathy No prior arterial thromboembolic event , include transient ischemic attack orcerebrovascular accident No prior diagnosis deep venous thrombosis , include pulmonary embolism , know thrombophilic condition ( e.g. , protein S , protein C , antithrombin III deficiency , Factor V Leiden Factor II G202 ` 0A mutation , homocysteinemia , antiphospholipid antibody syndrome ) No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious nonhealing wound , ulcer , bone fracture No evidence significant postoperative intracranial hemorrhage , define &gt; 1 cm blood postoperative MRI scan ( potentially addition postoperative scan ) obtain within past 14days No history allergic reaction Chinese hamster ovary cell product recombinanthuman antibodies No 31 day since definitive surgery Must receive prior chemotherapy , radiotherapy , immunotherapy , bone marrow transplant More 7 day since major surgical procedure recover For patient schedule receive bevacizumab : More 28 day since major procedure More 14 day since intermediate procedure More 7 day since minor procedure ( lumbar picture placement PICC line consider minor procedure ) No current anticancer agent No concurrent nonsteroidal antiinflammatory medication know inhibit platelet function know selectively inhibit cyclooxygenase activity No concurrent enzyme induce anticonvulsant No concurrent HDAC inhibitor ( e.g. , valproic acid ) No concurrent anticoagulant include systemic thrombolytic agent , heparin , low molecular weight heparin , warfarin except require maintain patency preexist permanent vascular catheter prevention thrombosis postoperative period</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>